Ref HAL: hal-04553207_v1
DOI: 10.1126/science.add5751
Exporter : BibTex | endNote
Résumé:

Magnetic skyrmions are topological magnetic textures that hold great promise as nanoscale bits of information in memory and logic devices. Although room-temperature ferromagnetic skyrmions and their current-induced manipulation have been demonstrated, their velocity has been limited to about 100 meters per second. In addition, their dynamics are perturbed by the skyrmion Hall effect, a motion transverse to the current direction caused by the skyrmion topological charge. Here, we show that skyrmions in compensated synthetic antiferromagnets can be moved by current along the current direction at velocities of up to 900 meters per second. This can be explained by the cancellation of the net topological charge leading to a vanishing skyrmion Hall effect. Our results open an important path toward the realization of logic and memory devices based on the fast manipulation of skyrmions in tracks.

Commentaires: This is the author’s version of the work. It is posted here bypermission of the AAAS for personal use, not for redistribution. The definitive version was published in Science 384, 307–312 (2024) , DOI: 10.1126/science.add5751

Ref HAL: hal-04539390_v1
DOI: 10.1039/D3MR00033H
Exporter : BibTex | endNote
Résumé:

Photoredox catalysis is becoming more and more prevalent in the 21st century as a new tool for organic and polymer synthesis. In addition, this domain clearly fits the expectations of the twelve principles of green chemistry. However, access to metal containing photosensitizers is not always straightforward and can require long reaction times, the use of toxic solvents and multi-step synthesis. These are definitely drawbacks that could be overcome with the use of novel technologies. In this report, we develop a one-pot two-step synthesis of iron(II) photosensitizers using ball-milling. Overall reaction times were drastically reduced, no solvent was needed during the reaction, and ten complexes could be isolated in high yields (73–99%). Using a transparent milling jar, the formation of the complexes could be followed using in situ Raman spectroscopy.

Ref HAL: hal-04517451_v1
DOI: 10.1001/jamanetworkopen.2023.52844
Exporter : BibTex | endNote
Résumé:

Importance : Pain is a common out-of-hospital symptom among patients, and opioids are often prescribed. Research suggests that overprescribing for acute traumatic pain is still prevalent, even when limits restricting opioid prescriptions have been implemented. Ketamine hydrochloride is an alternative to opioids in adults with out-of-hospital traumatic pain. Objective : To assess the noninferiority of intravenous ketamine compared with intravenous morphine sulfate to provide pain relief in adults with out-of-hospital traumatic pain. Design, Setting, and Participants : The Intravenous Subdissociative-Dose Ketamine Versus Morphine for Prehospital Analgesia (KETAMORPH) study was a multicenter, single-blind, noninferiority randomized clinical trial comparing ketamine hydrochloride (20 mg, followed by 10 mg every 5 minutes) with morphine sulfate (2 or 3 mg every 5 minutes) in adult patients with out-of-hospital trauma and a verbal pain score equal to or greater than 5. Enrollment occurred from November 23, 2017, to November 26, 2022, in 11 French out-of-hospital emergency medical units. Interventions : Patients were randomly assigned to ketamine (n = 128) or morphine (n = 123). Main Outcomes and Measures : The primary outcome was the between-group difference in mean change in verbal rating scale pain scores measured from the time before administration of the study drug to 30 minutes later. A noninferiority margin of 1.3 was chosen. Results : A total of 251 patients were randomized (median age, 51 [IQR, 34-69] years; 111 women [44.9%] and 140 men [55.1%] among the 247 with data available) and were included in the intention-to-treat population. The mean pain score change was −3.7 (95% CI, −4.2 to −3.2) in the ketamine group compared with −3.8 (95% CI, −4.2 to −3.4) in the morphine group. The difference in mean pain score change was 0.1 (95% CI, −0.7 to 0.9) points. There were no clinically meaningful differences for vital signs between the 2 groups. The intravenous morphine group had 19 of 113 (16.8% [95% CI, 10.4%-25.0%]) adverse effects reported (most commonly nausea [12 of 113 (10.6%)]) compared with 49 of 120 (40.8% [95% CI, 32.0%-49.6%]) in the ketamine group (most commonly emergence phenomenon [24 of 120 (20.0%)]). No adverse events required intervention. Conclusions and Relevance : In the KETAMORPH study of patients with out-of-hospital traumatic pain, the use of intravenous ketamine compared with morphine showed noninferiority for pain reduction. In the ongoing opioid crisis, ketamine administered alone is an alternative to opioids in adults with out-of-hospital traumatic pain. Trial Registration : ClinicalTrials.gov Identifier: NCT03236805